June 13, 2017
The Wall Street Journal CIO Journal covers biotechnology company Biogen Inc.’s completed proof of concept experiment with Accenture Labs and 1QBit, which shows that the resulting quantum-enabled methods have the potential to speed up drug discovery for diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s.
“After a two-month proof-of-concept test that took place earlier this year, researchers found that the quantum-enabled method allowed Biogen to more accurately compare molecular structures and get more information about the comparisons than any of its existing methods.
The structure of molecules, in addition to their chemical features, can be used to predict both positive effects of specific drugs, as well as the negative effects, such as the toxicity of a molecule.
With these more accurate comparison tools, Biogen will be able to cut expenses of screening different molecules for use in pharmaceuticals, because a more accurate initial comparison of molecules reduces the amount of trial, error and cost that is spent on drug development in the lab.”